Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

NCT03455972 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Safety and Efficacy

Interventions

BIOLOGICAL: anti-CD19 and anti-BCMA CAR
DRUG: Immunomodulatory drugs

Sponsor

The First Affiliated Hospital of Soochow University